Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q3 2023 · 10-Q
Revenue—
Net Income-$905.73K-$905.73KN/M vs Q3 2022 EPS Diluted-$0.82-$0.82N/M vs Q3 2022 Operating Income-$642,814N/M Operating Cash Flowderived-$364,049N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
ended Sep 30, 2023 · filed Nov 14, 2023 · 45 d after period end